Ladenburg Thalmann Financial Services’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio CADX Stock Details CADX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-4,425	Closed	-$40K	–	3991
2013 Q4	$40K	Sell	4,425 -12,925	-74%	-$93.3K	﹤0.01%	2077
2013 Q3	$109K	Buy	17,350 +8,500	+96%	+$54K	﹤0.01%	1353
2013 Q2	$60K	Buy	+8,850	New	+$61.6K	﹤0.01%	1615

Other funds holding CADX

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ladenburg Thalmann Financial Services's CADX Position: Q1 2014 in Review

Ladenburg Thalmann Financial Services sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 4,425 shares — an estimated $40K sold.

Ladenburg Thalmann Financial Services first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $109K in Q3 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

Ladenburg Thalmann Financial Services reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
Ladenburg Thalmann Financial Services sold 4,425 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $40K.
Ladenburg Thalmann Financial Services first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
Ladenburg Thalmann Financial Services's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $109K in Q3 2013.
3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q1 2014, filed 15 May 2014.